Hours af­ter block­buster patent win, My­lan asks the FDA to speed up an OK to mar­ket a gener­ic to Bio­gen’s Tec­fidera

Hours af­ter Bio­gen was hand­ed a key de­feat in fed­er­al court, los­ing patent pro­tec­tion that would have pro­tect­ed the multi­bil­lion-dol­lar fran­chise drug Tec­fidera to 2028, My­lan jumped in with a plan to ask the FDA for an ac­cel­er­at­ed OK of its copy­cat drug.

Look­ing at carv­ing up a mar­ket that de­liv­ered $4.4 bil­lion of Bio­gen’s rev­enue last year — 39% of the big biotech’s to­tal — My­lan doesn’t want to wait 5 months for a sched­uled de­ci­sion from the agency.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER